The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versi ...

The rush for weight loss drugs like Wegovy and diabetes drugs like Ozempic (which is also used for weight loss) has drained ...

Danish pharmaceutical giant Novo Nordisk sees a significant increase in profits and sales despite production constraints.

The company's popular drugs, Wegovy and Ozempic, both containing semaglutide, have been subject to shortages leading to the emergence of unregulated compounding. According to the FDA's adverse events ...

Dr. Whit Roberts of Health Utah says he is concerned about the financial costs and health risks potentially posed by popular weight loss drugs.

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

The Impact of New Weight Loss Drugs on Dietetics By Carrie Dennett, MPH, RDN Today’s Dietitian Vol. 26 No. 9 P. 14 What’s changed for weight-inclusive and weight management dietitians?

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.

Topline results were announced from a phase 3 clinical trial evaluating subcutaneous semaglutide in patients with MASH and liver fibrosis.

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...